Importance of Rebates and Future of Biosimilar Market | AMCP Nexus 2024
An optimistic outlook on the future of the biosimilar market driving down pharmaceutical drug spend.
In this discussion, Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca, highlights the critical role of rebates in maintaining affordable health plan premiums and accessibility of specialty drugs.
“A lot of people say that the biosimilar space is at risk - I don't believe that,” Gonzalez said. “I think it will continue to be one of the main drivers of lowering our overall pharmaceutical drug spend over the next five to 10 years.”
Abarca is a health IT company and pharmacy benefit manager. Gonzalez co-led the session, ‘Are Patients Getting a Fair Share of the Value of Biosimilars?’ today at AMCP Nexus, held at the MGM Grand in Las Vegas.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
